The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B. This evidence concerns the gene ZMPSTE24 and mandibuloacral dysplasia with type B lipodystrophy.